These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
252 related articles for article (PubMed ID: 27271860)
1. A mega-analysis of fixed-dose trials reveals dose-dependency and a rapid onset of action for the antidepressant effect of three selective serotonin reuptake inhibitors. Hieronymus F; Nilsson S; Eriksson E Transl Psychiatry; 2016 Jun; 6(6):e834. PubMed ID: 27271860 [TBL] [Abstract][Full Text] [Related]
2. Influence of baseline severity on the effects of SSRIs in depression: an item-based, patient-level post-hoc analysis. Hieronymus F; Lisinski A; Nilsson S; Eriksson E Lancet Psychiatry; 2019 Sep; 6(9):745-752. PubMed ID: 31303567 [TBL] [Abstract][Full Text] [Related]
3. Consistent superiority of selective serotonin reuptake inhibitors over placebo in reducing depressed mood in patients with major depression. Hieronymus F; Emilsson JF; Nilsson S; Eriksson E Mol Psychiatry; 2016 Apr; 21(4):523-30. PubMed ID: 25917369 [TBL] [Abstract][Full Text] [Related]
4. Systematic Review and Meta-Analysis: Dose-Response Relationship of Selective Serotonin Reuptake Inhibitors in Major Depressive Disorder. Jakubovski E; Varigonda AL; Freemantle N; Taylor MJ; Bloch MH Am J Psychiatry; 2016 Feb; 173(2):174-83. PubMed ID: 26552940 [TBL] [Abstract][Full Text] [Related]
5. Switching patients from daily citalopram, paroxetine, or sertraline to once-weekly fluoxetine in the maintenance of response for depression. Miner CM; Brown EB; Gonzales JS; Munir R J Clin Psychiatry; 2002 Mar; 63(3):232-40. PubMed ID: 11926723 [TBL] [Abstract][Full Text] [Related]
6. Are typical starting doses of the selective serotonin reuptake inhibitors sub-optimal? A meta-analysis of randomized, double-blind, placebo-controlled, dose-finding studies in major depressive disorder. Papakostas GI; Charles D; Fava M World J Biol Psychiatry; 2010 Mar; 11(2 Pt 2):300-7. PubMed ID: 20218793 [TBL] [Abstract][Full Text] [Related]
7. Remission with mirtazapine and selective serotonin reuptake inhibitors: a meta-analysis of individual patient data from 15 controlled trials of acute phase treatment of major depression. Thase ME; Nierenberg AA; Vrijland P; van Oers HJ; Schutte AJ; Simmons JH Int Clin Psychopharmacol; 2010 Jul; 25(4):189-98. PubMed ID: 20531012 [TBL] [Abstract][Full Text] [Related]
8. [Use of antidepressant drugs in schizophrenic patients with depression]. Micallef J; Fakra E; Blin O Encephale; 2006; 32(2 Pt 1):263-9. PubMed ID: 16910628 [TBL] [Abstract][Full Text] [Related]
9. Efficacy of selective serotonin reuptake inhibitors in the absence of side effects: a mega-analysis of citalopram and paroxetine in adult depression. Hieronymus F; Lisinski A; Nilsson S; Eriksson E Mol Psychiatry; 2018 Aug; 23(8):1731-1736. PubMed ID: 29155804 [TBL] [Abstract][Full Text] [Related]
10. Effectiveness and acceptability of sertraline and citalopram in major depressive disorder: pragmatic randomized open-label comparison. Matreja PS; Badyal DK; Khosla P; Deswal RS Hum Psychopharmacol; 2007 Oct; 22(7):477-82. PubMed ID: 17647298 [TBL] [Abstract][Full Text] [Related]
11. Dose-dependent influence of buspirone on the activities of selective serotonin reuptake inhibitors in the mouse forced swimming test. Redrobe JP; Bourin M Psychopharmacology (Berl); 1998 Jul; 138(2):198-206. PubMed ID: 9718290 [TBL] [Abstract][Full Text] [Related]
12. Incidence of early anxiety aggravation in trials of selective serotonin reuptake inhibitors in depression. Näslund J; Hieronymus F; Emilsson JF; Lisinski A; Nilsson S; Eriksson E Acta Psychiatr Scand; 2017 Oct; 136(4):343-351. PubMed ID: 28859218 [TBL] [Abstract][Full Text] [Related]
13. Persistence, switching, and discontinuation rates among patients receiving sertraline, paroxetine, and citalopram. Mullins CD; Shaya FT; Meng F; Wang J; Harrison D Pharmacotherapy; 2005 May; 25(5):660-7. PubMed ID: 15899727 [TBL] [Abstract][Full Text] [Related]
15. [Escitalopram is more effective than citalopram for the treatment of severe major depressive disorder]. Azorin JM; Llorca PM; Despiegel N; Verpillat P Encephale; 2004; 30(2):158-66. PubMed ID: 15107719 [TBL] [Abstract][Full Text] [Related]
16. Efficacy of controlled-release paroxetine in the treatment of late-life depression. Rapaport MH; Schneider LS; Dunner DL; Davies JT; Pitts CD J Clin Psychiatry; 2003 Sep; 64(9):1065-74. PubMed ID: 14628982 [TBL] [Abstract][Full Text] [Related]
17. Can we really accelerate and enhance the selective serotonin reuptake inhibitor antidepressant effect? A randomized clinical trial and a meta-analysis of pindolol in nonresistant depression. Portella MJ; de Diego-Adeliño J; Ballesteros J; Puigdemont D; Oller S; Santos B; Álvarez E; Artigas F; Pérez V J Clin Psychiatry; 2011 Jul; 72(7):962-9. PubMed ID: 21034693 [TBL] [Abstract][Full Text] [Related]
18. Spotlight on sertraline in the management of major depressive disorder in elderly patients. Muijsers RB; Plosker GL; Noble S CNS Drugs; 2002; 16(11):789-94. PubMed ID: 12383038 [TBL] [Abstract][Full Text] [Related]
19. An open-label study of duloxetine for the treatment of major depressive disorder: comparison of switching versus initiating treatment approaches. Wohlreich MM; Martinez JM; Mallinckrodt CH; Prakash A; Watkin JG; Fava M J Clin Psychopharmacol; 2005 Dec; 25(6):552-60. PubMed ID: 16282837 [TBL] [Abstract][Full Text] [Related]